Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer

NCT00116610 is registered in ClinicalTrials.gov with Poniard Pharmaceuticals as lead sponsor.

NCT NCT00116610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer
Lead sponsor
Poniard Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
March 31, 2008
Enrollment
75
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer